Entrada Therapeutics, Inc. (TRDA): Price and Financial Metrics


Entrada Therapeutics, Inc. (TRDA): $6.00

-0.12 (-1.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TRDA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TRDA Stock Price Chart Interactive Chart >

Price chart for TRDA

TRDA Price/Volume Stats

Current price $6.00 52-week high $36.85
Prev. close $6.12 52-week low $5.12
Day low $5.62 Volume 42,400
Day high $6.20 Avg. volume 94,506
50-day MA $7.63 Dividend yield N/A
200-day MA $0.00 Market Cap 188.20M

Entrada Therapeutics, Inc. (TRDA) Company Bio


Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.


TRDA Latest News Stream


Event/Time News Detail
Loading, please wait...

TRDA Latest Social Stream


Loading social stream, please wait...

View Full TRDA Social Stream

Latest TRDA News From Around the Web

Below are the latest news stories about Entrada Therapeutics Inc that investors may wish to consider to help them evaluate TRDA as an investment opportunity.

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference. The panel will be held on Monday, March 7, 2022 at 9:10 a.m. Eastern Time.

Yahoo | February 23, 2022

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | February 4, 2022

5AM Venture Management, LLC Buys Pear Therapeutics Inc, Entrada Therapeutics Inc, Sells ...

Investment company 5AM Venture Management, LLC (Current Portfolio) buys Pear Therapeutics Inc, Entrada Therapeutics Inc, sells Crinetics Pharmaceuticals Inc, Avidity Biosciences Inc, Silverback Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, 5AM Venture Management, LLC.

Yahoo | February 3, 2022

Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately. “We are thrilled to recognize the appointment of Jared to General Counsel,” said Dipal Doshi, President and Chief Executive Officer of Entra

Yahoo | January 5, 2022

Entrada Therapeutics (NASDAQ:TRDA) Trading Up 6.9%

Shares of Entrada Therapeutics Inc (NASDAQ:TRDA) were up 6.9% during mid-day trading on Thursday . The company traded as high as $17.27 and last traded at $17.16. Approximately 2,764 shares were traded during trading, a decline of 99% from the average daily volume of 259,330 shares. The stock had previously closed at $16.05. A number []

Transcript Daily | December 23, 2021

Read More 'TRDA' Stories Here

TRDA Price Returns

1-mo -10.45%
3-mo N/A
6-mo -75.13%
1-year N/A
3-year N/A
5-year N/A
YTD -64.95%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7253 seconds.